Acrivastine

{{Drugbox

| Verifiedfields = changed | verifiedrevid = 477241254 | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image =Acrivastine.png

| tradename = | Drugs.com = International Drug Names | MedlinePlus = a682619 | pregnancy_AU = | pregnancy_US = B | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = oral

| elimination_half-life = 1.5 hours | excretion = Renal

| CAS_number_Ref =  ^N | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank_Ref =  ^Y | ChemSpiderID_Ref =  ^Y | ChemSpiderID = 4447574 | UNII_Ref =  ^Y | UNII = A20F9XAI7W | KEGG_Ref =  ^Y | KEGG = D02760 | ChEMBL_Ref =  ^Y | ChEMBL = 1224 | ChEBI_Ref =  ^N | ChEBI = 83168

| C=22 | H=24 | N=2 | O=2 | molecular_weight = 348.438 g/mol | smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | StdInChI_Ref =  ^Y | StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | StdInChIKey_Ref =  ^Y | StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N }}

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.

This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a decongestant, pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.^[1]

Unlike cetirizine or loratadine, the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.^[2] Not to be taken by over 65’s, pregnant women or people with compromised liver or kidney function.

{{#ask: Page Name::Acrivastine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject:

 |Page Name=Acrivastine
 |Pill Name=SEMPREX_NDC_522440404.jpg
 |Drug Name=SEMPREX
 |Pill Ingred=ACRIVASTINE[ACRIVASTINE];PSEUDOEPHEDRINE HYDROCHLORIDE[PSEUDOEPHEDRINE]|+sep=;
 |Pill Imprint=404;SEMPREX;D
 |Pill Dosage=8 mg
 |Pill Color=Green|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Actient Pharmaceuticals, LLC
 |NDC=522440404

}}

{{#subobject:

 |Page Name=Acrivastine
 |Pill Name=Semprex-D_NDC_530140404.jpg
 |Drug Name=Semprex-D
 |Pill Ingred=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|+sep=;
 |Pill Imprint=404;SEMPREX-D
 |Pill Dosage=8 mg
 |Pill Color=Green;White|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=UCB, Inc.
 |NDC=530140404

}}